The study into mental ailment such as depression is facing a financial support crisis. The new treatment will be deferred and the next generation of neuroscience researchers will not be trained. It said that up to eighty percent of funding for brain research in Europe had conventionally come from the private sector.
According to report by the European College of Neuropsychopharmacology, private companies were drawing out due to defy of bringing drugs to the market. The report was the consequence of a height of more than sixty delegates of governments, universities, the pharmaceutical industry and patient groups.
It took much longer to develop the drugs for mental ailment approximately thirteen years on average. Those drugs had higher rate of failure and it was hard to get license for their use. In last decade only one anti-depressant known as agomelatine has been approved in Europe.
The lack of funding could escort to a generational crisis in neuroscience research and training. More public money should be invested in the brain research. The cost and burdens are really quite high, yet research attracts suspiciously low investment, explained Prof Guy Goodwin from the University of Oxford. Public investment in research should be someway associated to the burden of the disease.
The different ways are suggested by the report to encourage people to invest like increasing the length of patent of psychiatric drugs, which make them more money-spinning. The drugs which are no longer used by the pharmaceutical companies should be donated for research. The drugs discarded for treating Alzheimer’s disease, could be used in research for psychiatric turmoil.